Pediatrix Medical Group, Inc. (NYSE:MD) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Pediatrix Medical Group, Inc. (NYSE:MD) have been assigned an average recommendation of “Moderate Buy” from the six analysts that are covering the company, Marketbeat.com reports. Four research analysts have rated the stock with a hold recommendation, one has assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $21.00.

Several equities research analysts recently weighed in on MD shares. Weiss Ratings restated a “hold (c+)” rating on shares of Pediatrix Medical Group in a research note on Monday, December 29th. Truist Financial boosted their price objective on Pediatrix Medical Group from $17.00 to $24.00 and gave the stock a “hold” rating in a research note on Monday, November 10th. Zacks Research raised shares of Pediatrix Medical Group from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 21st. UBS Group upped their target price on shares of Pediatrix Medical Group from $16.50 to $23.00 and gave the company a “neutral” rating in a research report on Wednesday, November 5th. Finally, Wall Street Zen upgraded Pediatrix Medical Group from a “buy” rating to a “strong-buy” rating in a report on Saturday, October 4th.

Pediatrix Medical Group Trading Up 0.2%

Pediatrix Medical Group stock opened at $22.30 on Friday. The firm has a market capitalization of $1.91 billion, a price-to-earnings ratio of 11.73 and a beta of 0.73. Pediatrix Medical Group has a 52 week low of $11.84 and a 52 week high of $24.99. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 1.83. The company has a 50 day moving average price of $22.41 and a 200 day moving average price of $17.88.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings data on Monday, November 3rd. The company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.21. Pediatrix Medical Group had a net margin of 8.44% and a return on equity of 20.45%. The business had revenue of $492.88 million during the quarter, compared to analyst estimates of $476.45 million. During the same quarter in the previous year, the business earned $0.44 EPS. Pediatrix Medical Group’s quarterly revenue was down 3.6% compared to the same quarter last year. Research analysts forecast that Pediatrix Medical Group will post 1.38 EPS for the current year.

Insider Buying and Selling at Pediatrix Medical Group

In other news, Director Laura A. Linynsky sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $21.65, for a total transaction of $216,500.00. Following the sale, the director owned 32,232 shares in the company, valued at $697,822.80. This represents a 23.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Michael A. Rucker sold 10,478 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $23.00, for a total value of $240,994.00. Following the sale, the director owned 59,101 shares of the company’s stock, valued at approximately $1,359,323. This represents a 15.06% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 43,478 shares of company stock worth $972,924. Corporate insiders own 0.90% of the company’s stock.

Hedge Funds Weigh In On Pediatrix Medical Group

Several large investors have recently modified their holdings of the business. Royal Bank of Canada boosted its stake in shares of Pediatrix Medical Group by 23.8% in the 1st quarter. Royal Bank of Canada now owns 22,097 shares of the company’s stock valued at $320,000 after purchasing an additional 4,247 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Pediatrix Medical Group by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 51,253 shares of the company’s stock valued at $743,000 after buying an additional 2,251 shares in the last quarter. Empowered Funds LLC increased its position in shares of Pediatrix Medical Group by 3.2% during the first quarter. Empowered Funds LLC now owns 289,452 shares of the company’s stock worth $4,194,000 after acquiring an additional 9,007 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Pediatrix Medical Group by 4.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 268,506 shares of the company’s stock worth $3,891,000 after purchasing an additional 12,171 shares during the last quarter. Finally, Strs Ohio purchased a new stake in shares of Pediatrix Medical Group in the first quarter valued at about $690,000. Institutional investors own 97.71% of the company’s stock.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.